Vanguard Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.2M Sell
1,107,056
-7,900
-0.7% -$82.6K ﹤0.01% 2541
2026
Q2
$7.49M Buy
1,114,956
+7,936
+0.7% +$62.6K ﹤0.01% 2965
2026
Q1
$8.55M Buy
+1,107,020
New +$8.08M ﹤0.01% 2816

Other funds holding ARCT

Vanguard Capital Management's ARCT Position: Q3 2026 in Review

Vanguard Capital Management reduced its Arcturus Therapeutics (ARCT) stake by 0.71% in Q3 2026, selling an estimated $82.6K and leaving 1,107,056 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2541.

Vanguard Capital Management first reported a position in ARCT in Q1 2026 and has held it in 3 quarters since. 155 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Vanguard Capital Management held 1,107,056 shares of Arcturus Therapeutics worth $15.2M as of Q3 2026.
  • Vanguard Capital Management sold 7,900 Arcturus Therapeutics shares in Q3 2026, an estimated $82.6K.
  • Arcturus Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2541 holding.
  • Vanguard Capital Management first reported a position in Arcturus Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 155 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.